| Presynaptic inhibition | BTX cleaves SNAP-25, a protein essential for acetylcholine release at the neuromuscular junction |
| Temporary paralysis | This leads to chemical denervation of targeted muscles, reducing involuntary contractions |
| Duration | Effects typically last 3-4 months, requiring repeated injections for sustained benefit |
| Pain reduction | BTX reduces release of inflammatory mediators from nerve endings |
| Spasm relief | Decreased muscle spindle activity leads to reduced spasticity |
| Sensory gating | May interrupt aberrant sensory-motor feedback loops in damaged basal ganglia-cortical circuits |
| Cortical reorganization | Temporary paralysis allows for motor relearning |
| Neuroplasticity | May promote reorganization of motor maps in adjacent cortical regions |
| Long-term modulation | Repeated injections may lead to lasting changes in motor control patterns |
| Painful dystonic postures | Especially in upper extremities |
| Functional improvement | Enabling better hand use for activities of daily living |
| Gait improvement | Reducing scissoring or foot inversion during walking |
| KG Connections | 1 knowledge graph edges |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!